Is Sohonos a Biosimilar for Fulphila (Folotyn, FOP)?
Sohonos is a biosimilar candidate under development for fulranumab, which is the active ingredient in Fulphila (Folotyn, FOP) [1]. FOP, or fulranumab, is a recombinant human monoclonal antibody that blocks the activity of relaxin, a protein associated with an increased risk of cancer progression. It is primarily used to treat mantle cell lymphoma, a type of non-Hodgkin lymphoma.
What is expected to happen when Sohonos is approved?
Once approved, Sohonos will be a biosimilar replacement for Fulphila. As a biosimilar, it is expected to be highly similar to the reference product, with no clinically meaningful differences in safety, purity, potency, and efficacy, according to the FDA. Biosimilar approval can lead to lower prices for patients, as competition among manufacturers is introduced.
Can Sohonos be developed without infringing on patents?
Patent protection for fulranumab and other cancer treatments, such as [2], is still relevant. While biosimilar approvals are generally faster than the development of innovative therapies, it's unclear whether Sohonos will face patent disputes when seeking approval. The regulatory pathway of biosimilar drugs aims to balance the potential for patent infringement with innovation.
Comparison with existing treatments
The potential approval of Sohonos as a biosimilar will make it comparable to Fulphila in terms of clinical indications, safety, and efficacy. However, pricing and availability will differentiate it, as biosimilars are required to compete on price.
Potential impact on patients and healthcare system
By offering a more affordable alternative to a costly biologic drug like Fulphila, Sohonos may increase access to the treatment for mantle cell lymphoma patients, potentially alleviating the financial burden associated with cancer care.